about
sameAs
pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibilityThe yeast cyclin-dependent kinase inhibitor Sic1 and mammalian p27Kip1 are functional homologues with a structurally conserved inhibitory domainProtein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cellsBiochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1AHelicobacter pylori periplasmic receptor CeuE (HP1561) modulates its nickel affinity via organic metallophoresCell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potentialPhosphorylation of the Saccharomyces cerevisiae Grx4p glutaredoxin by the Bud32p kinase unveils a novel signaling pathway involving Sch9p, a yeast member of the Akt / PKB subfamily.Analysis of the interaction between piD261/Bud32, an evolutionarily conserved protein kinase of Saccharomyces cerevisiae, and the Grx4 glutaredoxinSer/Thr phosphorylation of hematopoietic specific protein 1 (HS1): implication of protein kinase CK2Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALLEffects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cellsHierarchical phosphorylation of a 50-kDa protein by protein tyrosine kinases TPK-IIB and C-Fgr, and its identification as HS1 hematopoietic-lineage cell-specific proteinFunctional homology between yeast piD261/Bud32 and human PRPK: both phosphorylate p53 and PRPK partially complements piD261/Bud32 deficiencyHematopoietic lineage cell specific protein 1 associates with and down-regulates protein kinase CK2.Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cellsDesign, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity.The selectivity of inhibitors of protein kinase CK2: an update.The carboxy-terminal domain of Grp94 binds to protein kinase CK2 alpha but not to CK2 holoenzyme.Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2).Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions.How do protein kinases recognize their substrates?Addiction to protein kinase CK2: a common denominator of diverse cancer cells?Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.Casein kinase: the triple meaning of a misnomer.Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain.Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.Cross-talk between the CK2 and AKT signaling pathways in cancer.Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.Assessment of CK2 constitutive activity in cancer cells.Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells.Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells.Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis.Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
P50
Q24320365-7A42619C-4232-40BA-AD46-68539F14C2F7Q24528174-43FDF8DF-B593-4C5F-AD54-BE74F14732C7Q24534101-EED6F268-FEBE-4351-A14C-F1D5C3AFDF03Q27641451-61071D1E-072B-422C-B23F-420D601F4FD7Q27655439-9ADAE275-7B56-4BF7-8DCF-7D1C78460B0CQ27670633-78AEE160-07D1-48C2-9FE0-705D40EA0C90Q27687932-16843851-F1AA-446A-86BC-FAACE56132FBQ27688944-651295CF-2A91-4BD1-B086-EAA7987D49F5Q27934675-CF57EAF1-61A7-402E-8DEE-5542724550D4Q27937634-AEB5BC2C-5500-4E33-A741-E27175FED245Q28144161-784B38DD-17CB-446A-96F7-89CED1D547D5Q28475897-6D929042-884E-433D-A270-491C264BD597Q28485087-CC7F9F6E-8899-48D3-9CC5-18D6042F3C04Q28574701-2BFABF81-EA75-4795-8B00-7F481A9BCD2BQ28609776-9B03B8CB-F1D7-4604-8C86-6EAE75532B63Q30175311-A26A6FCA-E36D-4FCD-A64C-B05DB8146A3FQ30987315-7A820DBB-5F6D-4735-AC36-46906A0DA780Q30992224-483C257D-DC01-415D-9D28-755AB44D94F6Q31117999-6474540D-534C-45A4-9033-502D2A98C73AQ33186326-AD80C7DD-B5AA-4C44-A773-1DB95D2861E6Q33347545-8EF50B0F-4FC0-48E8-B704-39B220B83192Q34091249-7F7664F6-2CAE-4C5F-A114-9A724FC8C7F9Q35106800-E1D79A7D-1D7B-41F4-8BE6-DB92A85ED6C7Q35158049-06315A9C-429B-4722-B2BD-2A4E00ADC04DQ36840425-2E3A7536-49B6-4513-93B8-58D81AC02C06Q37576535-9015681D-B463-4005-87BC-54426D5B2AF8Q37731326-AF4C8677-9DE2-462D-9773-4CB7EABA898CQ37979995-F3DA7AB5-6185-4553-B00A-AB6FECE72C23Q38211598-F52B8DE0-B142-4CC9-8758-4C237CED1440Q38777113-9CA5411D-4608-434A-B26D-DD72AC3DBCC6Q38820266-84F3D2FA-02AF-4FF0-B855-648F7D72F20EQ39053372-BE20CE2D-4224-4926-B1D2-57CE39C31915Q39217528-9800F944-982D-4080-805F-60D4F7B77EC2Q39393082-04FCF0AA-0856-41CB-8408-84310F7C873FQ39574810-E6683C02-548A-419E-AA90-B2E039765F41Q39637925-81330D4E-B666-4CB2-87FD-4A8F86EDD9FDQ39815562-03528764-1568-40A4-9140-DAB835A58FE9Q39937276-F172E3B7-0939-4B26-9A6E-691BBACC9C44Q39971411-B238B868-F9E0-4A98-B7E5-D836B20F733AQ40135888-EC35F81D-C76D-47C2-AAB3-86CE11847610
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Ruzzene
@ast
Maria Ruzzene
@en
Maria Ruzzene
@es
Maria Ruzzene
@nl
Maria Ruzzene
@sl
type
label
Maria Ruzzene
@ast
Maria Ruzzene
@en
Maria Ruzzene
@es
Maria Ruzzene
@nl
Maria Ruzzene
@sl
prefLabel
Maria Ruzzene
@ast
Maria Ruzzene
@en
Maria Ruzzene
@es
Maria Ruzzene
@nl
Maria Ruzzene
@sl
P106
P1153
7006366475
P21
P31
P496
0000-0001-8712-8151